IL161832A0 - Pharmaceutical composition for inducing an immune response in a human or animal - Google Patents

Pharmaceutical composition for inducing an immune response in a human or animal

Info

Publication number
IL161832A0
IL161832A0 IL16183202A IL16183202A IL161832A0 IL 161832 A0 IL161832 A0 IL 161832A0 IL 16183202 A IL16183202 A IL 16183202A IL 16183202 A IL16183202 A IL 16183202A IL 161832 A0 IL161832 A0 IL 161832A0
Authority
IL
Israel
Prior art keywords
inducing
animal
human
immune response
pharmaceutical composition
Prior art date
Application number
IL16183202A
Other languages
English (en)
Original Assignee
Dandrit Biotech As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dandrit Biotech As filed Critical Dandrit Biotech As
Publication of IL161832A0 publication Critical patent/IL161832A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL16183202A 2001-11-29 2002-11-29 Pharmaceutical composition for inducing an immune response in a human or animal IL161832A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200101770 2001-11-29
US33670601P 2001-12-07 2001-12-07
PCT/DK2002/000802 WO2003045427A2 (en) 2001-11-29 2002-11-29 Pharmaceutical composition for inducing an immune response in a human or animal

Publications (1)

Publication Number Publication Date
IL161832A0 true IL161832A0 (en) 2005-11-20

Family

ID=26069102

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16183202A IL161832A0 (en) 2001-11-29 2002-11-29 Pharmaceutical composition for inducing an immune response in a human or animal

Country Status (11)

Country Link
US (2) US7771998B2 (de)
EP (1) EP1448229B1 (de)
JP (1) JP2005515192A (de)
AT (1) ATE446106T1 (de)
AU (1) AU2002365291B2 (de)
DE (1) DE60234115D1 (de)
DK (1) DK1448229T3 (de)
ES (1) ES2335396T3 (de)
IL (1) IL161832A0 (de)
RU (1) RU2313365C2 (de)
WO (1) WO2003045427A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ755300A0 (en) 2000-05-17 2000-06-08 Monash University Immune potentiating compositions
DE10112851C1 (de) * 2001-03-16 2002-10-10 Gsf Forschungszentrum Umwelt Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
ES2294346T3 (es) * 2002-11-28 2008-04-01 Peter Kufer Rt-pcr en tiempo real novedosa para la deteccion sensible de multiples transcripciones del gen mage.
CA2587712C (en) * 2004-11-18 2013-02-12 National University Of Corporation Hiroshima University Method and kit for expressing protein under regulation of the expression from repeated sequence formed by gene amplification and transformant
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
WO2007123591A1 (en) 2006-01-30 2007-11-01 Ludwig Institute For Cancer Research Ctsp cancer-testis antigens
GB0612342D0 (en) * 2006-06-21 2006-08-02 Glaxosmithkline Biolog Sa Method
GB0700284D0 (en) * 2007-01-08 2007-02-14 Glaxosmithkline Biolog Sa Combination therapy
CN101755045B (zh) 2007-05-17 2014-02-12 生物载体株式会社 树突状细胞的制备方法
EP2318040A4 (de) * 2008-07-24 2013-05-01 Univ Central Florida Res Found Auf krebsstammzellen gerichtete therapie
KR101361416B1 (ko) * 2008-10-08 2014-02-21 인트렉손 코포레이션 다수의 면역조절자를 발현하는 조작된 세포 및 그 용도
KR20120059581A (ko) 2009-08-24 2012-06-08 윌슨 울프 매뉴팩처링 다중 종양 항원 또는 다중 바이러스에 대해 특이성을 갖는 ｃｔｌ주의 생성
US20130195800A1 (en) * 2010-03-23 2013-08-01 Intrexon Corporation Vectors Conditionally Expressing Therapeutic Proteins, Host Cells Comprising the Vectors, and Uses Thereof
GB201013443D0 (en) * 2010-08-11 2010-09-22 Cytovac As Compositions and methods for producing dendritic cells
PH12018501678B1 (en) 2011-08-30 2022-08-10 Astex Pharmaceuticals Inc Decitabine derivative formulations
CN105288602A (zh) * 2011-10-20 2016-02-03 新干细胞肿瘤学有限责任公司 具有γ干扰素的抗原呈递癌症疫苗
JP5871228B2 (ja) * 2011-10-31 2016-03-01 国立大学法人佐賀大学 慢性副鼻腔炎の検出方法
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
EP2812431B1 (de) 2012-02-09 2019-07-17 Baylor College Of Medicine Peptidmischungen zur erzeugung multiviraler ctl mit breiter spezifität
WO2014007669A1 (ru) * 2012-07-04 2014-01-09 Volgushev Sergei Anatolievich Аутологичная клеточная вакцина для лечения онкологических заболеваний и способ ее получения
EP3316685A4 (de) 2015-07-02 2019-03-13 Otsuka Pharmaceutical Co., Ltd. Lyophilisierte pharmazeutische zusammensetzungen
IL298359B2 (en) 2015-09-18 2025-12-01 Baylor College Medicine Immunogenic antigen identification from a pathogen and correlation to clinical efficacy
GB201520542D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
EP3661522A2 (de) 2017-08-03 2020-06-10 Otsuka Pharmaceutical Co., Ltd. Arzneimittelverbindung und reinigungsverfahren dafür
WO2020018413A1 (en) 2018-07-15 2020-01-23 Enochian BioPharma, Inc. Methods and compositions using recombinant dendritic cells for cancer therapy
EP3903811A1 (de) 2020-05-01 2021-11-03 R.G.C.C. Holdings AG Pharmazeutische zusammensetzung und verfahren zur induzierung einer immunantwort
EP3981425A1 (de) 2020-10-12 2022-04-13 R.G.C.C. Holdings AG Sars-cov-2-impfstoffe
CA3119597C (en) 2020-10-12 2023-07-11 R.G.C.C. Holdings AG Sars-cov-2 vaccines

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443832A (en) * 1990-04-16 1995-08-22 Institut Swisse De Recherches Experimentales Sur Le Cancer Hydroxyapatite-antigen conjugates and methods for generating a poly-Ig immune response
AU2087401A (en) 1999-12-10 2001-06-18 Epimmune, Inc. Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions
US20040241176A1 (en) * 2000-04-27 2004-12-02 Ap Cells. Inc. Method of producing membrane vesicles
US20040087532A1 (en) 2001-03-09 2004-05-06 Banchereau Jacques F. Method of treating malignancies through induction of blood immune responses

Also Published As

Publication number Publication date
US20090029457A1 (en) 2009-01-29
RU2004119548A (ru) 2005-03-27
US20060051324A1 (en) 2006-03-09
WO2003045427A2 (en) 2003-06-05
DK1448229T3 (da) 2010-03-08
RU2313365C2 (ru) 2007-12-27
DE60234115D1 (de) 2009-12-03
US7723107B2 (en) 2010-05-25
US7771998B2 (en) 2010-08-10
HK1086750A1 (zh) 2006-09-29
ES2335396T3 (es) 2010-03-26
AU2002365291A1 (en) 2003-06-10
EP1448229A2 (de) 2004-08-25
JP2005515192A (ja) 2005-05-26
WO2003045427A3 (en) 2004-03-25
ATE446106T1 (de) 2009-11-15
EP1448229B1 (de) 2009-10-21
AU2002365291B2 (en) 2007-11-01

Similar Documents

Publication Publication Date Title
WO2003045427A3 (en) Pharmaceutical composition for inducing an immune response in a human or animal
DE69734605D1 (de) Abgeschwächter salmonellenstamm, gebraucht als vehikel zur oralen immunisierung
WO2004091543A3 (en) Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
PT1053256E (pt) Anticorpos para o receptor de morte 4 (dr4) e utilizações destes
ECSP105739A (es) Anticuerpos de neutralización contra gdf-8
TR199800607T1 (xx) Dendritik h�cre uyar�c� fakt�r�.
NZ306653A (en) Isolated dna il-17 receptors
NZ333607A (en) Method of stimulating the immune system by transfecting dendritic cells
IL172854A0 (en) Autologous self-tolerance inducing cells of monocytic origin and their use in pharmaceutical preparations
PL343245A1 (en) Methods for identifying inducers and inhibitors of proteolytic antibodies, compositions and their uses
ES2530769T3 (es) Métodos para la activación de células T in vivo por células dendríticas pulsadas con antígeno
AU2002223462A1 (en) Use of cd28-specific monoclonal antibodies for stimulating blood cells that lackcd28
WO2002010350A1 (en) Method of proliferating natural killer cells
NZ505834A (en) Compositions containing polypeptides isolated from mycobacterium vaccae and methods for their use
WO2004012681A3 (en) Cancer vaccines containing epitopes of oncofetal antigen
IL155514A0 (en) Fusion cells and cytokine compositions for treatment of disease
WO2002034287A3 (en) Therapeutic vaccine formulations containing chitosan
WO2004037198A3 (en) Antibody-mediated induction of tumor cell death
NZ507829A (en) Vaccine adjuvants for immunotherapy of melanoma
AU8026800A (en) Use of allogeneic cell lines to load antigen-presenting cells to elicit or eliminate immune responses
ATE412763T1 (de) Antikörper-abhängige vergrösserung der alphavirus-infektvität
WO2002017935A3 (en) A method of transplantation using chemotherapy-treated allogeneic cells that enhance immune responses without graft versus host disease
WO2004072262A3 (en) Cultured cd14+ antigen presenting cells
MY127452A (en) Vaccines.
WO1999012945A3 (en) Hydrophobic glycosylamine derivatives, compositions, and methods for use